[go: up one dir, main page]

CL2018003167A1 - Selección de cepas bacterianas útiles en el tratamiento de alergias. - Google Patents

Selección de cepas bacterianas útiles en el tratamiento de alergias.

Info

Publication number
CL2018003167A1
CL2018003167A1 CL2018003167A CL2018003167A CL2018003167A1 CL 2018003167 A1 CL2018003167 A1 CL 2018003167A1 CL 2018003167 A CL2018003167 A CL 2018003167A CL 2018003167 A CL2018003167 A CL 2018003167A CL 2018003167 A1 CL2018003167 A1 CL 2018003167A1
Authority
CL
Chile
Prior art keywords
treatment
allergies
selection
bacterial strains
strains useful
Prior art date
Application number
CL2018003167A
Other languages
English (en)
Inventor
Bo Möllstam
James Versalovic
Bhanu Priya Ganesh
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of CL2018003167A1 publication Critical patent/CL2018003167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

CEPAS BACTERIANAS ÚTILES EN LA PROFILAXIS, INHIBICIÓN Y/O EL TRATAMIENTO DE UNA ALERGIA EN UN MAMÍFERO SON SELECCIONADAS MEDIANTE DETECTAR CEPAS BACTERIANAS POR SU CAPACIDAD DE PRODUCIR DIACILGLICEROL QUINASA (DAGK). LUEGO SE SELECCIONA UNA CEPA BACTERIANA QUE SEA CAPAZ DE PRODUCIR DAGK PARA SU USO EN LA PROFILAXIS, INHIBICIÓN Y/O TRATAMIENTO DE LA ALERGIA.
CL2018003167A 2016-05-09 2018-11-08 Selección de cepas bacterianas útiles en el tratamiento de alergias. CL2018003167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1650620 2016-05-09

Publications (1)

Publication Number Publication Date
CL2018003167A1 true CL2018003167A1 (es) 2018-12-21

Family

ID=58873850

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003167A CL2018003167A1 (es) 2016-05-09 2018-11-08 Selección de cepas bacterianas útiles en el tratamiento de alergias.

Country Status (11)

Country Link
US (2) US11135255B2 (es)
EP (1) EP3454874A1 (es)
JP (1) JP7030716B2 (es)
CN (1) CN109195612A (es)
AU (1) AU2017262408A1 (es)
BR (1) BR112018072511A2 (es)
CA (1) CA3023867A1 (es)
CL (1) CL2018003167A1 (es)
MX (1) MX392754B (es)
SG (1) SG11201809551TA (es)
WO (1) WO2017196235A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007925A (es) * 2019-12-24 2022-09-29 Univ Iowa State Res Found Inc Control de histamina para promover la salud y controlar la enterocolitis usando composiciones probioticas y/o enzimas, que degrada histamina.
JP7515153B2 (ja) * 2020-03-06 2024-07-12 学校法人麻布獣医学園 乳酸菌含有組成物
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN114317326B (zh) * 2021-12-06 2023-09-12 浙江工商大学 一种用于缓解过敏反应的清酒乳杆菌及制备方法
CN115025130A (zh) * 2022-06-02 2022-09-09 广东南芯医疗科技有限公司 罗伊氏乳杆菌e9在制备治疗或预防过敏性疾病药物中的应用
CN116376758B (zh) * 2023-03-15 2024-07-02 广东南芯医疗科技有限公司 詹氏乳杆菌ls06及其在制备治疗或预防过敏性疾病药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (da) * 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
KR100507417B1 (ko) 2003-01-27 2005-08-10 (주) 피엘바이오 알레르기 질환 예방 및 치료 기능을 가진 유산균과 이를 함유한 항알레르기 제품
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
EP2674493B1 (en) * 2006-04-13 2017-12-27 Arrowhead Research Corporation RNAi-mediated inhibition of histamine receptor H1-related conditions
JP2008127365A (ja) * 2006-11-24 2008-06-05 Kowa Co アレルギー性疾患の予防及び／又は治療剤
EP2323689A1 (en) * 2008-08-18 2011-05-25 Manel Jordana Treatment and/or prevention of peanut induced anaphylaxis
JP2011254773A (ja) * 2010-06-11 2011-12-22 Bio Plan:Kk 乳酸菌の菌株及びこれを利用したアレルギー抑制剤
WO2012012390A1 (en) * 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
JP6195268B2 (ja) * 2013-07-18 2017-09-13 国立大学法人徳島大学 鼻炎の予防治療装置
BR112017019660A2 (en) * 2015-03-26 2018-05-15 Biogaia Ab Histamine-producing lactic acid bacterial strain and method of selecting a lactic acid bacterial strain for use

Also Published As

Publication number Publication date
US11135255B2 (en) 2021-10-05
US20190142877A1 (en) 2019-05-16
MX392754B (es) 2025-03-24
CA3023867A1 (en) 2017-11-16
WO2017196235A1 (en) 2017-11-16
US20220008491A1 (en) 2022-01-13
JP7030716B2 (ja) 2022-03-07
CN109195612A (zh) 2019-01-11
US12201656B2 (en) 2025-01-21
EP3454874A1 (en) 2019-03-20
AU2017262408A1 (en) 2018-11-15
MX2018013660A (es) 2019-02-28
BR112018072511A2 (pt) 2019-03-12
JP2019520801A (ja) 2019-07-25
SG11201809551TA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CL2018003167A1 (es) Selección de cepas bacterianas útiles en el tratamiento de alergias.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
MX378854B (es) Composiciones que comprenden cepas bacterianas.
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691991A1 (ru) Мультиспецифические антитела
AR099619A1 (es) Polímero viscosificante para el tratamiento de una formación subterránea
CR20160379A (es) Anticuerpos biespecificos anti-il 13/il-17 y sus usos
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
ECSP17029203A (es) Inhibidor de cinasa aurora a
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
AR097533A1 (es) Tratamiento de pozos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
CL2018003417A1 (es) Nuevos compuestos.